PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
- Conditions
- Urothelial CancerNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 61
- Registration Number
- NCT03472560
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇰🇷National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
🇨🇳Chi Mei Hospital, Liouying, Tainan City, Liouying District, Taiwan
Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2020-06-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT03469336
- Locations
- 🇩🇪
bioskin GmbH, Hamburg, Germany
🇩🇪Rothaar Studien GmbH, Berlin, Germany
Trial in Adult Subjects With Acute Migraines
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1811
- Registration Number
- NCT03461757
- Locations
- 🇺🇸
Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States
🇺🇸Sundance Clinical Research, Saint Louis, Missouri, United States
🇺🇸Ki Health Partners LLC DBA New England Institute for Clinical Research, Stamford, Connecticut, United States
Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Conditions
- Follicular Lymphoma (FL)Small Cell Lung Cancer (SCLC)Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- Drug: Mervometostat (PF-06821497)
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 343
- Registration Number
- NCT03460977
- Locations
- 🇺🇸
Urological Associates of Southern Arizona, P.C ., Tucson, Arizona, United States
🇺🇸Banner-University Medical Center Tucson, Tucson, Arizona, United States
🇺🇸The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT03448692
- Locations
- 🇺🇸
The Cleveland Clinic - Investigational Drug Pharmacy, Cleveland, Ohio, United States
🇺🇸The Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸The Kirklin Clinic of University Alabama Birmingham Hospital, Birmingham, Alabama, United States
Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT03448172
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®
- Conditions
- Breast Neoplasm
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 540
- Registration Number
- NCT03445637
- Locations
- 🇰🇷
Pfizer Tower, Seoul, Korea, Republic of
Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 51690
- Registration Number
- NCT03441633
- Locations
- 🇪🇸
IDIAP Jordi Gol, Barcelona, Cataluña, Spain
A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
- Conditions
- Dilated CardiomyopathyLamin A/C Gene Mutation
- Interventions
- Drug: ARRY-371797 (PF-07265803)Other: Placebo
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 77
- Registration Number
- NCT03439514
- Locations
- 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
🇳🇴Oslo University Hospital, Rikshospitalet, Oslo, Norway
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3164
- Registration Number
- NCT03422822
- Locations
- 🇺🇸
Ds Research, Clarksville, Indiana, United States
🇺🇸Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
🇺🇸The Indiana Clinical Trials Center, Plainfield, Indiana, United States